DOCSLIB.ORG

42 Antipsychotic Drugs Oliver Freudenreich, MD, Donald C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
42 Antipsychotic Drugs Oliver Freudenreich, MD, Donald C 42 Antipsychotic Drugs Oliver Freudenreich, MD, Donald C. Goff, MD, and David C. Henderson, MD KEY POINTS • All antipsychotics share dopamine2 blockade as the second-generation antipsychotics, metabolic problems presumed main mechanism of action. (e.g., weight gain, dyslipidemia, hyperglycemia) have • Primary symptom targets of antipsychotics are positive emerged as major problems. symptoms (disorganization, delusions, and • First- and second-generation antipsychotics are equally hallucinations) and agitation; their efficacy for negative effective for non-refractory patients with schizophrenia. symptoms and cognitive deficits of schizophrenia is For refractory patients, olanzapine, and in particular questionable. Increasingly, antipsychotics are used for clozapine, have been the most efficacious. treatment of mood disorders. • Clozapine has minimal or no risk of inducing EPS and • Historically, antipsychotics have been grouped is the most effective antipsychotic. However, its clinical into first-generation antipsychotics (typical or use is limited to refractory patients because of serious conventional antipsychotics, which are all characterized side effects (including metabolic problems and by their risk of extrapyramidal symptoms [EPS]) and agranulocytosis that requires white blood cell count second-generation antipsychotics (with a reduced risk of monitoring). EPS; hence they are called “atypical” antipsychotics). • Currently available antipsychotics have variable efficacy However, antipsychotics within each class are not and tolerability and need to be selected on the basis of necessarily interchangeable. individualized risk–benefit assessments (i.e., balancing • The main risks of first-generation antipsychotics are the degree of symptomatic response with day-to-day neurological side effects (e.g., dystonias, akathisia, tolerability and long-term medical morbidity, parkinsonism, tardive dyskinesia [TD]); for most particularly cardiovascular risk). INTRODUCTION with chlorpromazine and found remarkable tranquilizing effects in their most agitated and psychotic patients.2,3 By In this chapter, we will review the basic pharmacology of 1954,y Dela and Deniker had published six papers on their antipsychotics, emphasizing the differential efficacy and side- clinical experience with chlorpromazine. They noted in 1955 effect profiles between first- and second-generation antipsy- that both chlorpromazine and the dopamine-depleting agent chotics, including clozapine, based on the schizophrenia reserpine shared antipsychotic efficacy and neurological side literature. While antipsychotics are used more broadly than for effects that resembled Parkinson’s disease. They coined the the treatment of schizophrenia, antipsychotic agents have term neuroleptic to describe these effects. In 1956 Frank Ayd4,5 received FDA approval for additional indications, particularly described acute dystonia and fatal hyperthermia with chlor- for the treatment of mood disorders for which they are used promazine. The first reports of tardive dyskinesia (TD) were routinely. A recent meta-analysis found that antipsychotics published by Sigwald and colleagues in 1959.6 were significantly more effective for mania than were mood Smith Kline purchased chlorpromazine from the French 1 stabilizers. The specific treatment considerations with regards pharmaceutical company Rhône-Poulenc, and in 1954 chlor- to choice of an antipsychotic for the major psychiatric syn- promazine received approval from the Food and Drug Admin- dromes (e.g. schizophrenia, bipolar disorder, depression, istration (FDA) for the treatment of psychosis. Almost autism) can be found in the chapters on these conditions. immediately the care of psychotic patients was transformed. In the US the traditional practice of life-long “warehousing” of individuals with schizophrenia in large state psychiatric HISTORY hospitals gave way to the new outpatient community psychia- try movement. An additional 10 antipsychotic compounds Chlorpromazine and the Early Agents were rapidly synthesized and approved for clinical use. This In 1952, Henri Laborit, a French naval surgeon, was experi- included a series of phenothiazines, the thioxanthenes (that menting with combinations of preoperative medications to were derived from phenothiazines), and haloperidol, which reduce the autonomic stress of surgical procedures. He tried a was synthesized from meperidine by Paul Janssen in 1958. In newly-synthesized antihistamine, chlorpromazine, and was 1967 haloperidol, the last “neuroleptic,” was approved by the impressed by its calming effect. He noted that patients seemed FDA and, because of its relative selectivity for dopamine2 (D2) indifferent about their impending surgery, yet they were not receptors and paucity of non-neurological side effects, became overly sedated. Convinced that the medication had potential the market leader. for the care of psychiatric patients, Laborit urged colleagues to By 1964, several multi-center trials sponsored by the Veter- test his hypothesis. Eventually a surgical colleague told his ans Administration and the National Institutes of Mental brother-in-law, the psychiatrist Pierre Deniker, about Leborit’s Health (NIMH) were completed, comparing the rapidly discovery. growing list of antipsychotic agents. These landmark studies Deniker and Jean Delay, who was the chairman of his each enrolled several hundred patients and were the first department at the Hôpital Sainte-Anne in Paris, experimented large clinical trials to be conducted in the new field of 475 Downloaded for Rohul Amin ([email protected]) at Uniformed Services Univ of the Health Sciences from ClinicalKey.com by Elsevier on September 21, 2018. For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved. 476 PART X Treatment Approaches psychopharmacology. The phenothiazines were found to be TABLE 42-1 Timeline of Antipsychotics in the United States highly effective and superior to placebo, barbiturates, and reserpine. With the exception of promazine and mepazine, the First-Generation Antipsychotics (11 Agents)* phenothiazines were found to be of equivalent efficacy, Chlorpromazine (Thorazine) 1954 although they differed in their side-effect profiles. In the Haloperidol (Haldol) 1967 NIMH collaborative study of over 400 acutely ill patients, 75% Second-Generation Antipsychotics (10 Agents) of patients were at least moderately improved with chlorpro- mazine, thioridazine, or fluphenazine, compared to only 23% Clozapine (Clozaril) 1989 7 Risperidone (Risperdal) 1993 with placebo. While reports of efficacy were impressive, the Olanzapine (Zyprexa) 1997 goal of identifying differences in efficacy between drugs that Quetiapine (Seroquel) 1997 mightw allo matching of specific drugs with subgroups of Ziprasidone (Geodon) 2001 patients was not realized. Aripiprazole (Abilify) 2002 The discovery by Carlsson and Lindqvist8 in 1963 that Paliperidone (Invega) 2006 chlorpromazine increased turnover of dopamine in the brain Iloperidone (Fanapt) 2009 led to the hypothesis that dopamine receptor-blockade was Asenapine (Saphris) 2009 responsible for antipsychotic effects. This was confirmed in Lurasidone (Latuda) 2010 1976y b Creese and colleagues,9 who demonstrated that the Note: The year given for each agent denotes the year of FDA approval. antipsychotic potency of a wide range of agents correlated *Only the first and last agents are listed for first-generation closely with affinity for the D2 ,receptor which explained the antipsychotics. equivalency of efficacy between agents since all were acting via the same mechanism. The dopamine hypothesis led to a reli- ance on animal models sensitive to D2 blockade as a screen for discovering potential antipsychotic drugs, with the result that new mechanisms were not intentionally explored. efficacy compared to haloperidol. Risperidone and olanzapine rapidly replaced the first generation of neuroleptics, particu- Clozapine, the First Atypical Antipsychotic larly after clinicians became convinced that the risk of TD was substantially lower. However, it soon became apparent that The discovery of the first antidepressant, imipramine, led to risperidone markedly elevated serum prolactin levels and that the synthesis of related heterotricylic compounds, among olanzapine produced weight gain in some patients to a degree which clozapine, a dibenzodiazepine derivative, was synthe- previously seen only with clozapine. Quetiapine, ziprasidone, sized in 1958 by the Swiss company Wander. Clozapine was and aripiprazole were subsequently approved in the US, based initially a disappointment, because it did not produce in largely on reduced EPS; these agents did not convincingly animal models the behavioral effects associated with an anti- demonstrate superior efficacy compared to older neuroleptics. depressant or the neurological side effects associated with an Like risperidone and olanzapine, these last three agents acted antipsychotic. Clinical trials proceeded in Europe but were via D2 and 5-HT2A receptors; aripiprazole differed from the halted in 1975 after reports of 17 cases of agranulocytosis in other second-generation antipsychotics by possessing partial 10 Finland, 8 of which were fatal. However, the impression agonist activity at the D2 receptor rather than full antagonism. among researchers that clozapine possessed unique clinical Risperidone became the first atypical agent available as a long- characteristics led the manufacturer, Sandoz, to sponsor a acting
Load more

Recommended publications
  • Jean Delay Preamble
    1 Barry Blackwell: Pioneers and Controversies in Psychopharmacology Chapter Six: Jean Delay Preamble Jean Delay is perhaps best remembered for the discovery of Chlorpromazine, the first effective drug for the treatment resistant psychotic men and women who filled the world’s asylums in the mid twentieth century. Compared to Delay’s other scientific and literary accomplishments, as told in Driss Moussai’s biography, his role in this discovery was largely conceptual and clinically modest, but as was customary in hierarchical French academia, Delay’s name came first on scientific publications. The clinical work was conducted by Pierre Deniker and an intern in his department, J.M. Harl, who died prematurely in a mountain climbing accident. Deniker described the early work in detail (Deniker, 1970) when he received the Taylor Manor Award for the discovery and presented his paper, “Introduction of Neuroleptic Chemotherapy.” “Logically a new drug was tried in cases resistant to all existing therapies. We had scarcely treated 10 patients - with all due respect to fervent adherents of statistics - when our conviction proved correct. It was supported by the sudden, great interest of nursing personnel, who had always been reserved about innovations.” When the first paper was presented to the French Medico-Psychological Society at a meeting on shock or sleep therapy the effect was described as ”neuroleptic” – effecting the neuron - in cases of “manic excitation, and more generally, psychotic patients who were often resistant to shock or sleep therapy.” The specific effects were noted on “agitation, aggressiveness and delusive conditions of schizophrenia which improved. Contact with patients could be re-established, but deficiency symptoms did not change markedly.” When six definitive papers were published between May and June 1952 these observations had been made on only 38 patients without any attempt at controlled design (Delay, Deniker and Harl 1952).
    [Show full text]
  • A Modo De Fichas Sobre Clásicos De La Psiquiatría: Jean Delay Y El Nacimiento De La Psicofarmacología Moderna
    A modo de fichas sobre clásicos de la Psiquiatría: Jean Delay y el nacimiento de la psicofarmacología moderna Reda Rahmani y Luis Pacheco Su vida: Jean Delay nació el 14 de noviembre de 1907 en El recorrido académico de Jean Delay es la Bayona, hijo único de Maurice Delay y Berthe historia de una conquista sin pausa. Mihura. Según su colega Pierre Deniker, tenía Dirigiéndose a él, Léon Bérard, miembro de la absoluta admiración por su madre y le dedicaría academia francesa, dirá: “su carrera nos en vida gran parte de sus obras. Su padre, antes sorprende por una especie de regularidad e de llegar a ser alcalde de la ciudad, era el infalibilidad en el éxito”. Regular e infalible pero, principal cirujano de la misma, y deseó que su sobre todo, muy precoz. hijo le sucediera en el oficio. Frustrar ese Jean Delay acabó el bachillerato en la rama de destino fue el inicio de una carrera sin filosofía con 14 años, sin sospechar que la precedentes en el panorama de la pregunta sobre las relaciones entre lo físico y lo neuropsiquiatría francesa. moral, en su examen final de disertación filosófica, le iba finalmente a ocupar gran parte de su vida. Gracias a un permiso del ministro de Educación comenzó la carrera de medicina a los 15 años de edad, en París. Posteriormente, fue un amigo de la familia, Pasteur Vallery-Radot, quién tuvo que viajar de París a Bayona para anunciarle al padre de nuestro protagonista que éste jamás será cirujano. A los 20 años estaba ya especializándose en neurología en el hospital de la Pitié-Salpêtrière en el servicio de Lévy- Fig .1: Portada del libro de Delay “Les dissolutions de la Valensi, su primer maestro, para estudiar memoire”.
    [Show full text]
  • Psychiatry and Stigmatization
    EDITOR’S NOTE Psychiatry and Stigmatization Amir Zarrinpar Editor WHEN MURRAY AND LOPEZ IN 1996 INTRODUCED THE IDEA OF THE DIS- Stuart P. Weisberg ability-adjusted life-year (which measures healthy years lost to pre- Columbia University College of Physicians mature mortality or disability), it should have come as no surprise when and Surgeons they found that 7 of the top 10 causes of disability in industrialized Deputy Editors countries were mental disorders. Unipolar major depression and al- Alison J. Huang, MPhil University of California ON THE COVER cohol abuse, the top 2 on this list, caused more years lost to disability San Francisco Christopher Adams, 1 School of Medicine Columbia University, than the next 5 combined. Pam Rajendran College of Physicians The public remains reluctant, however, to respond to this public Boston University and Surgeons, School of Medicine health problem. A 1996 poll found that most people would be un- Tripods, white Associate Editors willing to support paying for mental illness treatment if it would lead stoneware, low-fire 2 Rahul Rajkumar underglaze, 22.8 ϫ to increases in their premiums or taxes. Legislators appear similarly Yale University ϫ School of Medicine 22.8 22.8 cm. reluctant to support measures that would make mental health care more Teri A. Reynolds, PhD accessible. In his report on mental health, the US surgeon general urged University of California San Francisco proper public education to remove the misperceptions and stigma of School of Medicine mental illnesses that prevent them from being treated like other types John F. Staropoli of medical illness.3 This task will likely prove difficult as mental ill- Columbia University College of Physicians nesses have suffered from misperception and stigma ever since and Surgeons ancient times.
    [Show full text]
  • Autographes & Manuscrits
    _25_06_15 AUTOGRAPHES & MANUSCRITS & AUTOGRAPHES Pierre Bergé & associés Société de Ventes Volontaires_agrément n°2002-128 du 04.04.02 Paris 92 avenue d’Iéna 75116 Paris T. +33 (0)1 49 49 90 00 F. +33 (0)1 49 49 90 01 Bruxelles Avenue du Général de Gaulle 47 - 1050 Bruxelles Autographes & Manuscrits T. +32 (0)2 504 80 30 F. +32 (0)2 513 21 65 PARIS - JEUDI 25 juIN 2015 www.pba-auctions.com VENTE AUX ENCHÈRES PUBLIQUES PARIS Pierre Bergé & associés AUTOGRAPHES & MANUSCRITS DATE DE LA VENTE / DATE OF THE AUCTION Jeudi 25 juin 2015 - 13 heures 30 June Thursday 25th 2015 at 1:30 pm LIEU DE VENTE / LOCATION Drouot-Richelieu - Salle 8 9, rue Drouot 75009 Paris EXPOSITION PRIVÉE / PRIVATE VieWinG Sur rendez-vous à la Librairie Les Autographes 45 rue de l’Abbé Grégoire 75006 Paris T. + 33 (0)1 45 48 25 31 EXPOSITIONS PUBLIQUES / PUBlic VieWinG Mercredi 24 juin de 11 heures à 18 heures Jeudi 25 juin de 11 heures à 12 heures June Wednesday 24th from 11:00 am to 6:00 pm June Thursday 25th from 11:00 am to 12:00 pm TÉLÉPHONE PENDANT L’EXPOSITION PUBLIQUE ET LA VENTE T. +33 (0)1 48 00 20 08 CONTACTS POUR LA VENTE Eric Masquelier T. + 33 (0)1 49 49 90 31 - [email protected] Sophie Duvillier T. + 33 (0)1 49 49 90 10 - [email protected] EXPERT POUR LA VENTE Thierry Bodin Syndicat Français des Experts Professionnels en Œuvres d'Art 45 rue de l'Abbé Grégoire, 75006 Paris T.
    [Show full text]
  • Research at the Centre Hospitalier Sainte-Anne Psychiatry and Neurosciences RESEARCH ACTIVITY REPORT 2016 the CH Sainte-Anne and Its Research Activity
    Clinical Research • Psychiatry • Neurosciences Translational Research • Reversible Continuum Pre-clinical / Clinical / Public Health Research Basic Research • Collaborative Research Research at the Centre Hospitalier Sainte-Anne Psychiatry and Neurosciences RESEARCH ACTIVITY REPORT 2016 The CH Sainte-Anne and its research activity The Sainte-Anne site has been at the forefront of major discoveries, advances and innovations History of research at CHSA 3 in scientific and biomedical matters in the domain of fundamental and clinical psychiatry and neurosciences. 4 The topics and domains of A pioneer amongst non-teaching hospital centres, the CH Sainte-Anne has the advantage of research being a hospital specialising in brain disorders, combining different departments of psychiatry, child psychiatry and clinical neurosciences. Sainte-Anne, a unique site of interaction between 6 The advantages of the psychiatry and neurosciences, covers a large population and a high number of active records Sainte-Anne site for (more than 34,000 patients treated every year at the hôpital Sainte-Anne). research Headquarters of the Regional Hospital Group (GHT - Groupement Hospitalier de Territoire) “Paris-Psychiatrie et Neurosciences”, the CH Sainte-Anne is at the heart of Parisian psychiatric 12 Typology / qualification and challenges and referrals for neurosciences. Lastly, Sainte-Anne also intends to strengthen its regulatory procedures of bonds with other actors in biomedical research, and especially with the Inserm (through the New Psychiatry and Neurosciences Centre) and the Pasteur Institute, with which Sainte- clinical research projects Anne is currently affiliated. The goal of the “Paris – Psychiatrie & Neurosciences” GHT is to find ways to better describe and to gain a better understanding of the brain and its disorders The topics and domains of 16 (pathophysiology) in order to ensure better prevention and better healthcare, owing to its research of the clinical units strategic vision of integrating basic as well as clinical research in Psychiatry and Neurosciences.
    [Show full text]
  • This Article Appeared in a Journal Published by Elsevier. the Attached
    This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues. Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited. In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier’s archiving and manuscript policies are encouraged to visit: http://www.elsevier.com/copyright Author's personal copy r e v u e n e u r o l o g i q u e 1 6 8 ( 2 0 1 2 ) 3 8 9 – 4 0 2 Available online at www.sciencedirect.com History of Neurology Figures and Institutions of the neurological sciences in Paris from 1800 to 1950. Part IV: Psychiatry and psychology Les figures et institutions des sciences neurologiques a` Paris de 1800 a` 1950. Partie IV : psychiatrie et psychologie a b c,d e,f, J. Poirier , F. Clarac , J.-G. Barbara , E. Broussolle * a Hoˆpital Pitie´-Salpeˆtrie`re, 47-83, boulevard de l’Hoˆpital, 75651 Paris cedex 13, France b CNRS, UMR 6196, laboratoire plasticite´ et physiopathologie de la motricite´, universite´ Aix-Marseille-II, 31, chemin Joseph-Aiguier, 13402 Marseille cedex 20, France c CNRS, UMRS 7102, laboratoire de neurobiologie des processus adaptatifs, universite´ Pierre-et-Marie-Curie, case 14, 4, place Jussieu,
    [Show full text]
  • Thomas A. Ban Barry Blackwell, Samuel Gershon, Peter R. Martin, Gregers Wegener
    International Network for the History of Neuropsychopharmacology Educational E-Books Thomas A. Ban Barry Blackwell, Samuel Gershon, Peter R. Martin, Gregers Wegener INHN 2014 Edited by Peter R. Martin International Network for the History of Neuropsychopharmacology Risskov 2015 2 Contents PREFACE ...................................................................................................................................... 10 HISTORICAL DICTIONARY IN NEUROPSYCHOPHARMACOLOGY ................................. 14 Active reflex by Joseph Knoll ................................................................................................ 16 Amine oxidase by Joseph Knoll............................................................................................. 17 Anna Monika Prize by Samuel Gershon ................................................................................ 18 Ataraxic drugs by Carlos R. Hojaij ........................................................................................ 19 Catecholaminergic activity enhancer effect by Joseph Knoll ................................................ 20 Component specific clinical trial by Martin M. Katz ............................................................ 21 Dahlem Conferences by Jules Angst ..................................................................................... 22 Delay’s classification by Carlos R. Hojaij ............................................................................. 23 Depressors of affect by Carlos R. Hojaij ..............................................................................
    [Show full text]
  • Jean Delay – Une Lumière En Dehors De Son Siécle
    JEAN DELAY – UNE LUMIÈRE EN DEHORS DE SON SIÉCLE M. MARINESCU1, AL. MARINESCU2 Abstract. The authors evoke the personnality and the path left by Jean Delay (1907–1987), a great French psychiatrist, who introduced the neuroleptics in the treatment of mental diseases, but also an important personality of literature and philosophy of science. On pense que c’est Philippe Pinel en 1801, qui à libéré les fous. C’est vrai, il les à sorti des prisons ou ils partageaient les mêmes cellules que les violeurs et les criminels. Mais il s’agit là juste d’un premier regard sur la maladie mentale car, une fois sortis des geôles, ils ont été mis dans des établissements psychiatriques asilaires, dont la sortie était très rare du vivant du patient. Il a fallu attendre un siècle et demi de plus, avant l’étude de la chlorpromazine, découverte par Henri Laborit et utilisé à l’hôpital militaire du Val De Grace pour provoquer l’hibernation artificielle. Jean Delay, en 1952 est chef de service à l’hôpital Sainte-Anne, à Paris : c’est lui, avec ses collaborateurs, J.M. Harl et P. Deniker, qui va étudier les effets sédatifs de la chlorpromazine dans les états d’agitation des patients psychiatriques, appelant l’effet de la molécule « ganglioplégique » puis « neuroplégique » et enfin, ce qui reste toujours valable aujourd’hui, « neuroleptique », avant de présenter au Congrès Mondial de Psychiatrie, en 1961, une classification des substances psychotropes en fonction de leur activité sur le système nerveux central. Rien que pour cela, le nom de Jean Delay devrait être gardé en mémoire.
    [Show full text]
  • History of Psychopharmacology
    CP15CH02_Braslow ARjats.cls April 12, 2019 13:51 Annual Review of Clinical Psychology History of Psychopharmacology Joel T. Braslow1,2 and Stephen R. Marder1,3 1Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, California 90095-1759, USA; email: [email protected] 2Department of History, University of California, Los Angeles, California 90095-1759, USA 3Veterans Administration Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, California 90073, USA Annu. Rev. Clin. Psychol. 2019. 15:25–50 Keywords First published as a Review in Advance on psychopharmacology, history, antipsychotics, antidepressants, mental February 20, 2019 illness, treatment The Annual Review of Clinical Psychology is online at clinpsy.annualreviews.org Abstract https://doi.org/10.1146/annurev-clinpsy-050718- We live in an age of psychopharmacology. One in six persons currently takes 095514 a psychotropic drug. These drugs have profoundly shaped our scientific and Annu. Rev. Clin. Psychol. 2019.15:25-50. Downloaded from www.annualreviews.org Copyright © 2019 by Annual Reviews. cultural understanding of psychiatric disease. By way of a historical review, All rights reserved we try to make sense of psychiatry’s dependency on psychiatric drugs in the Access provided by University of California - Los Angeles UCLA on 05/29/19. For personal use only. care of patients. Modern psychopharmacology began in 1950 with the syn- thesis of chlorpromazine. Over the course of the next 50 years, the psychi- atric understanding and treatment of mental illness radically changed. Psy- chotropic drugs played a major part in these changes as state hospitals closed and psychotherapy gave way to drug prescriptions.
    [Show full text]
  • Magic Bullet in the Head? Psychiatric Revolutions and Their Aftermath Nicolas Henckes
    Magic Bullet in the Head? Psychiatric Revolutions and Their Aftermath Nicolas Henckes To cite this version: Nicolas Henckes. Magic Bullet in the Head? Psychiatric Revolutions and Their Aftermath. Jeremy A. Greene; Flurin Condrau; Elizabeth S. Watkins. Therapeutic Revolutions: Pharmaceuticals and Social Change in the Twentieth Century, University of Chicago Press, pp.65-96, 2016, 9780226390871. hal-01449102 HAL Id: hal-01449102 https://hal.archives-ouvertes.fr/hal-01449102 Submitted on 30 Jan 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Magic Bullet in the Head? Psychiatric Revolutions and Their Aftermath Nicolas Henckes a a. Chargé de Recherche CNRS CERMES3 – Centre de Recherche Médecine , Sciences, Santé, Santé mentale et Société - CNRS UMR8211 – INSERM U988 – EHESS – UPD 7 rue Guy Môquet 94801 Villejuif Cedex [email protected] Prepublication version of: Henckes, Nicolas 2016, Magic Bullet in the Head? Psychiatric Revolutions and Their Aftermath, In: Jeremy A. Greene, Flurin Condrau and Elizabeth S. Watkins, eds., Therapeutic Revolutions: Pharmaceuticals and Social Change in the Twentieth Century, Chicago, University of Chicago Press, pp. 65-96 Abstract: This chapter examines the emergence and rise of a rhetoric of revolutionary change in western Psychiatry from the post-war period to the 2000s.
    [Show full text]
  • Terese Lemperiere
    IN THE BEGINNING IN PARIS THÉRÈSE LEMPÉRIÈRE When did you join the department of Psychiatry in Paris? I began in Sainte Anne in the service of Professor Delay in 1950 as an intern - a resident. It was my first job in psychiatry. I stayed there for a year and after that I went to the Salpétrière to finish my training in neurology with Alajouanine and Garcin and in child neuropsychiatry with Michaux. During this year in Sainte Anne I had the chance to get to know psychiatry before the arrival of the neuroleptics. At that time we were giving a lot of electroshock and the Insulin Coma treatment of Sakel but if all of that failed one felt very helpless. Were you with the university department or were you in the hospital? I was in the service of Professor Delay which was the only university service of psychiatry in the hospital. I was working with Deniker who at that time was a young assistant. How many patients were there in the hospital at the time? In the service of Professor Delay there was approximately 200 patients. Altogether in Sainte Anne there were approximately 1000 patients. The services were overcrowded and living conditions were very mediocre. The medical heads of departments were competent practitioners but they were working in very difficult conditions with few collaborators. Sainte Anne was the only psychiatric hospital within the boundaries of Paris. How many patients did you have to look after? Approximately 50 but this was under the supervision of Deniker. In Delay’s service, which was a university service, the number of medical people was much greater than in other services.
    [Show full text]
  • Neuroleptic Was Coined by Jean Delay and Pierre Deniker, Who First Used the Drug in Psychiatry, and Means "Attaching to the Neuron’
    CPS001727-0001 Source: Toxic i-’s3,chiatrv. Dr Peter t3reggin. Published bv Harper (’ffflms HALOPERIDOL (HALDOL) NEUROLEPTIC Neuroleptic was coined by Jean Delay and Pierre Deniker, who first used the drug in psychiatry, and means "attaching to the neuron’. Delay and Deniker intended the term to underscore the toxic impact of the drug on nerve cells. [pg 61 ] The neuroleptics are the most frequently prescribed drugs in mental hospitals, and they are widely used as well in board-and-care homes, nursing homes, institutions for people with mental retardation, children’s facilities, and prisons. They also are ~ven to millions of patients in public clinics and to hundreds of thousands in private psychiatric offices. Too often they are prescribed for anxiety,, sleep problems, and other difficulties in a manner that runs contrary to the usual recommendations. And too often they are administered to children with behaviour problems, even children who are living at home and going to school. [pg 62] Of the estimated two million patients in nursing homes, many of them are on neuroleptics. [pg 63] In recent years, haloperidoi, under the trade name Haldol, has become the most prescribed neuroleptic. [pg 63/64] A picture of the use of drugs in the UK is given by Lucy Johnstone: ’40 per cent of patients on major tranquillizers did not have a diagnosis Of schizophrenia, while nearly one-half of the patients on antidepressants did not have a diagnosis of clinical depression. A previous survey had found that 40 per cent of patients with problems of a known physical origin such as dementia were taking major tranquillizers, which would hardly have enhanced whatever degree of mental functioning they still had.’ [pg 64i65] The Clinical Impact of the Neuroleptics Textbooks of psychiatry and review articles claim that the neuroleptics have a specific antipsychotic effect.
    [Show full text]